uncertainty and create new possibilities in impossibility. This is the "core" of the development of Shandong Pharmaceutical Glass Group. Since the establishment of the factory
in 1970, in addition to coping with the constant changes in the macro environment, new and old rivals have also been like a merry-go-round, fighting hard one after another, making a more pragmatic pharmaceutical glass thrive. In the past 53 years, from traditional manufacturing to full intellectualization, new growth points have been cultivated; from imitative innovation to original innovation, foreign monopoly has been broken; from "zero technology" to domestic exclusive core technology..
Today's Pharmaceutical Glass has delivered a brilliant answer sheet: the annual output of its leading products, molded antibiotic bottles, is more than 9 billion, and the annual output of pharmaceutical butyl rubber stoppers is 4.8 billion. It has established long-term and stable cooperative relations with more than 1200 Chinese and foreign pharmaceutical manufacturers, such as Harbin Pharmaceutical Group, Beijing Shuanghe Pharmaceutical, Pfizer Pharmaceutical, Novartis and Glaxo. At present, Shandong Pharmaceutical Glass Company has become the leading professional manufacturer of pharmaceutical glass in China, and its production scale ranks first in Asia.
From a production workshop supporting a pharmaceutical factory to a world-famous leading enterprise in the pharmaceutical packaging industry, what did the pharmaceutical glass do right? What reference can it provide for the development of other private enterprises in Zibo?
Quality is king
. What can you do in a minute? The answer was obtained in the project workshop of 1.8 billion medium borosilicate control series products of pharmaceutical glass.
Walking into the ampoule production workshop, 10 automatic production lines are running at high speed, and three or four workers are busy around the production line, carrying out operations in different positions. "Automatic feeding, preheating, heating, wire drawing, mouth making, bottom sealing, a total of 36 stations in a machine, only one minute to complete, followed by dotting, annealing, inspection, packaging, which is the main process of ampoule manufacturing." Hu Yonggang, chairman of Pharmaceutical Glass, said as he picked up a 2ml brown ampoule from the production line.
"You may not know that for the same products, we use all the production lines imported from Italy and Germany, one production line of Italian ocmi is more than 500000 euros, one production line of tube bottles is more than 1.2 million euros, and we use all the imported production lines to compete with the domestic production lines of less than 100000 yuan in the same industry." The purpose is to provide the best quality packaging for Chinese pharmaceutical enterprises, so that the Chinese people can use safe and reassuring drugs.
Hu Yonggang believes that in order to achieve sustainable development of enterprises, we must achieve two extremes, one of which is the ultimate quality.
As an intelligent manufacturing enterprise, Pharmaceutical Glass has continuously increased its investment, adopted the latest technology, improved the automation of manufacturing series, improved production process and quality control means, and developed new varieties. In the whole production process, all advanced production equipment from Europe and the United States are introduced to realize automatic inspection and packaging of products, thus improving the yield of glass products and laying a solid foundation for industrial transformation, upgrading and innovation.
By exchanging quality for quantity, pharmaceutical glass has led the iterative upgrading of domestic molded bottle packaging. In order to meet the demand for high-end drug packaging materials in China, Pharmaceutical Glass has completed the breakthrough in research and development and large-scale production of medium borosilicate mold resistant bottles in the shortest time. At present, medium borosilicate mold resistant bottles are mainly used in high-end drugs such as blood products and contrast agents, and extend to common cephalosporins and penicillins in an all-round way. "In the future, the development of such products is expected to become the pillar products of pharmaceutical glass companies and an important support to promote the high-quality development of pharmaceutical glass." Hu Yonggang said.
Innovation as the soul
leads another extreme of enterprise development, which is "extreme innovation" in Hu Yonggang's view. "We benefit from timely and active change and innovation in the face of development, keep up with the pace of industry development, take the initiative to innovate and create, from the beginning of automatic control of line machines, automatic packaging, automatic control of kilns, etc., to overcome the technical problems of first-class water-resistant glass, a class of alkali-resistant glass, and then to the mass production of medium borosilicate glass products." It is the embodiment of the ultimate innovation.
In 2014, when domestic pharmaceutical glass was still dominated by "low quality and quantity", pharmaceutical glass smelled the risk that traditional pharmaceutical glass would be replaced. At that time, borosilicate pharmaceutical bottles were just emerging in the international market, seizing this opportunity, pharmaceutical glass embarked on the road of independent innovation.
After three years of experiments, the pharmaceutical glass has successfully broken through the bottleneck and realized the mass production of medium borosilicate glass tubes. With the help of the successful experience in the research and development of medium borosilicate mould-resistant bottles, combined with the technology of producing low borosilicate tubes for many years, the melting and forming technology of medium borosilicate glass tubes has been broken through again, and the situation that medium borosilicate glass tubes have been monopolized by three glass manufacturing giants, Schott of Germany, Corning of the United States and NEG of Japan, has been completely broken. On the basis of the continuous maturity of the industrial chain of bottle + stopper + cap, a new industrial chain of medium borosilicate tube + pre-encapsulation + tube bottle has been formed, which realizes the self-sufficiency of raw materials for medium borosilicate tube series products. At present, the company has 172 scientific and technological achievements and 106 patented technologies. The self-developed glass bottles with high white material, light weight and thin wall for pharmaceutical use have obtained the national new product certificate, and the borosilicate glass products have filled the gaps in China.
"We are a generation of production, a generation of research and development, and a generation of reserves to achieve a virtuous circle of technological innovation." Hu Yonggang said with deep feeling that transformation and upgrading is the only way to revitalize the pharmaceutical glass. Although it is a long process from research and development to landing, the enterprise has the belief of perseverance and never giving up, so that the pharmaceutical glass can remain invincible.
The industrial chain has leaped
to the production line of the first phase of the project of borosilicate pharmaceutical glass with an annual output of 2 billion, the equipment is running at full capacity, the machines are roaring on the spot, and the workers are wearing protective suit to grasp the production. "We are stepping up the construction of the second phase of the project with the kinetic energy advantage of the first phase." Hu Yonggang said that this year, a total investment of 1.1 billion yuan is planned for the construction of an annual output of 4 billion borosilicate pharmaceutical glass bottles and the expansion and transformation of pre-filled syringes. The project with an annual output of 4 billion glass bottles for borosilicate medicine is mainly used for freeze-dried biological agents, powder injections, vaccines, genetic engineering drugs, etc. The expansion and transformation project of pre-filled syringes is an excellent new and old kinetic energy conversion project in the province, aiming at the international and domestic biopharmaceutical field in the future market. The two projects are planned to be completed in 2024, with an additional output value of 4 billion yuan after the project is completed and put into operation.
These projects outline the innovative layout of the whole industry chain of medicine and glass-on the basis of bottle + cap + plug, tube + pre-filling + tube bottle, extend the new chain of pre-filling nest + support + box and steel needle + plunger + push rod, and accelerate the development and production of pre-filling nest, support, box and other external supporting packaging plastic products; Imported components such as push rods, plungers and steel needles for internal assembly will be localized within three years, so as to truly realize chain extension and cluster development, so that enterprises can gain a firm foothold in the process of global industrial chain reconstruction.
"Faced with the uncertain market environment, what we need to do is to constantly consolidate our internal strength, promote project construction, rely on the platform to do a good job in scientific research and innovation, keep up with the pace of industry development, and constantly enrich product categories." Looking forward to the future, Hu Yonggang is full of confidence. He said that Shandong Pharmaceutical Glass Company will continue to cultivate the field of pharmaceutical glass packaging, aiming at the world's leading edge and building the world's pharmaceutical glass.
浙公网安备33010802003254号